257 related articles for article (PubMed ID: 29087143)
1. What do pharmaceuticals really cost in the long run?
Lakdawalla D; MacEwan JP; Dubois R; Westrich K; Berdud M; Towse A
Am J Manag Care; 2017 Aug; 23(8):488-493. PubMed ID: 29087143
[TBL] [Abstract][Full Text] [Related]
2. OSTEOPOROSIS DRUGS MARKETED IN THE UNITED STATES: GENERIC COMPETITION, PRICING STRUCTURE, AND DISPERSION AMONG PAYERS.
Balkhi B; Seoane-Vazquez E; Rodriguez-Monguio R
Int J Technol Assess Health Care; 2016 Jan; 32(6):385-392. PubMed ID: 28065194
[TBL] [Abstract][Full Text] [Related]
3. Association of authorized generic marketing with prescription drug spending on antidepressants from 2000 to 2011.
Cheng N; Banerjee T; Qian J; Hansen RA
J Am Pharm Assoc (2003); 2017; 57(3):341-348. PubMed ID: 28400255
[TBL] [Abstract][Full Text] [Related]
4. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
Kesselheim AS; Avorn J; Sarpatwari A
JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
[TBL] [Abstract][Full Text] [Related]
5. Association of Generic Competition With Price Decreases in Physician-Administered Drugs and Estimated Price Decreases for Biosimilar Competition.
Dickson SR; Kent T
JAMA Netw Open; 2021 Nov; 4(11):e2133451. PubMed ID: 34779844
[TBL] [Abstract][Full Text] [Related]
6. Product-line extensions and pricing strategies of brand-name drugs facing patent expiration.
Hong SH; Shepherd MD; Scoones D; Wan TT
J Manag Care Pharm; 2005; 11(9):746-54. PubMed ID: 16300418
[TBL] [Abstract][Full Text] [Related]
7. Generic script share and the price of brand-name drugs: the role of consumer choice.
Rizzo JA; Zeckhauser R
Int J Health Care Finance Econ; 2009 Sep; 9(3):291-316. PubMed ID: 19130220
[TBL] [Abstract][Full Text] [Related]
8. Decreasing utilization and increasing prices of brand-name oral contraceptive pills: Implications to societal costs and market competition.
Zhang JX
PLoS One; 2020; 15(6):e0234463. PubMed ID: 32525965
[TBL] [Abstract][Full Text] [Related]
9. Brand Medications and Medicare Part D: How Eye Care Providers' Prescribing Patterns Influence Costs.
Newman-Casey PA; Woodward MA; Niziol LM; Lee PP; De Lott LB
Ophthalmology; 2018 Mar; 125(3):332-339. PubMed ID: 28625684
[TBL] [Abstract][Full Text] [Related]
10. Price competition in pharmaceuticals - Evidence from 1303 Swedish markets.
Granlund D; Bergman MA
J Health Econ; 2018 Sep; 61():1-12. PubMed ID: 30007260
[TBL] [Abstract][Full Text] [Related]
11. Long-term Medicaid excess payments from alleged price manipulation of generic lorazepam.
Bian B; Gorevski E; Kelton CM; Guo JJ; Martin Boone JE
J Manag Care Pharm; 2012 Sep; 18(7):506-15. PubMed ID: 22971204
[TBL] [Abstract][Full Text] [Related]
12. The effect of generic competition on the price of brand-name drugs.
Lexchin J
Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
[TBL] [Abstract][Full Text] [Related]
13. Association Between Market Competition and Prices of Generic Topical Dermatology Drugs.
Li DG; Joyce C; Mostaghimi A
JAMA Dermatol; 2018 Dec; 154(12):1441-1446. PubMed ID: 30383117
[TBL] [Abstract][Full Text] [Related]
14. The Evolution of Supply and Demand in Markets for Generic Drugs.
Frank RG; McGuire TG; Nason I
Milbank Q; 2021 Sep; 99(3):828-852. PubMed ID: 34075623
[TBL] [Abstract][Full Text] [Related]
15. Endogenous versus exogenous generic reference pricing for pharmaceuticals.
Antoñanzas F; Juárez-Castelló CA; Rodríguez-Ibeas R
Int J Health Econ Manag; 2017 Dec; 17(4):413-432. PubMed ID: 28508248
[TBL] [Abstract][Full Text] [Related]
16. Trends in Prices of Popular Brand-Name Prescription Drugs in the United States.
Wineinger NE; Zhang Y; Topol EJ
JAMA Netw Open; 2019 May; 2(5):e194791. PubMed ID: 31150077
[TBL] [Abstract][Full Text] [Related]
17. Generic Drugs in the United States: Policies to Address Pricing and Competition.
Gupta R; Shah ND; Ross JS
Clin Pharmacol Ther; 2019 Feb; 105(2):329-337. PubMed ID: 30471089
[TBL] [Abstract][Full Text] [Related]
18. Determinants of Market Exclusivity for Prescription Drugs in the United States.
Kesselheim AS; Sinha MS; Avorn J
JAMA Intern Med; 2017 Nov; 177(11):1658-1664. PubMed ID: 28892528
[TBL] [Abstract][Full Text] [Related]
19. Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme.
Karnon J; Edney L; Sorich M
Aust Health Rev; 2017 Mar; 41(1):1-6. PubMed ID: 26954612
[TBL] [Abstract][Full Text] [Related]
20. Are drug prices subject to creative destruction? Evidence from the US, 1997-2017.
Lichtenberg FR
Health Econ; 2021 Aug; 30(8):1910-1932. PubMed ID: 33987916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]